Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3882477 | 0.88 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL19153077 | 0.86 | CA14 (0.41) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL8480025 | 0.84 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL26962278 | 0.84 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL5360201 | 0.84 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL9050850 | 0.84 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL100090 | 0.84 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL960818 | 0.84 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL9051516 | 0.84 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL2369243 | 0.84 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4596535-A1 | DRUG FOR TREATING HUMAN TUMOR BY ERF3A TARGETED PROTEIN DEGRADATION MECHANISM | Suzhou Degen Bio-Medical Co, Ltd. (CN) | 2025-08-06 | — | — | EP | disclosed |
| US-20250213701-A1 | MEDICAMENT FOR TREATING HUMAN TUMOR BASED ON ERF3A-TARGETING PROTEOLYSIS MECHANISM | SUZHOU DEGEN BIO-MEDICAL CO., LTD. (CN) | 2025-07-03 | — | — | US | disclosed |
| CN-118119598-A | Medicine for treating human tumor by eRF3a targeting protein degradation mechanism | 苏州德亘生物医药有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117801051-A | Medicine for treating human tumor by eRF3a targeting protein degradation mechanism | 苏州德亘生物医药有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-0990653-B1 | 2-OXOIMIDAZOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-09-15 | — | — | EP | disclosed |
| EP-1221443-B1 | SUBSTITUTED IMIDAZOLIDINONE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-09-01 | — | — | EP | disclosed |
| US-6699880-B1 | STIMULATE MUSCARINIC ACETYLCHOLINE RECEPTORS M4, ANALGESICS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-02 | — | — | US | disclosed |
| EP-1221443-A1 | SUBSTITUTED IMIDAZOLIDINONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-07-10 | — | — | EP | disclosed |
| US-6258825-B1 | ANALGESIC, A RELIEVER AGAINST TOLERANCE TO A NARCOTIC ANALGESIC REPRESENTED BY MORPHINE, REMEDY FOR PARKINSONISM, A REMEDY FOR CHOREA, AN ANTIDEPRESSANT, A REMEDY FOR DIABETES INSIPIDUS, A REMEDY FOR POLYURIA, OR HYPOTENSION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-07-10 | — | — | US | disclosed |
| EP-0990653-A1 | 2-OXOIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2000-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213701-A1 | MEDICAMENT FOR TREATING HUMAN TUMOR BASED ON ERF3A-TARGETING PROTEOLYSIS MECHANISM | XIAP, TP53, UBE3A | HDAC6 2324/4885HDAC1 3482/4885HDAC2 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.